CEFOXITIN FOR INJECTION 1 G
CEFOXITIN (CEFOXITIN SODIUM) : 1 G · DIN 02128187 · TEVA CANADA LIMITED
Health Canada status: MARKETED
What is CEFOXITIN FOR INJECTION?
CEFOXITIN FOR INJECTION 1 G contains CEFOXITIN (CEFOXITIN SODIUM) : 1 G. It is listed in the Health Canada Drug Product Database under DIN 02128187, held by TEVA CANADA LIMITED, supplied as POWDER FOR SOLUTION for INTRAVENOUS ; INTRAMUSCULAR administration. Health Canada currently lists it as marketed, status dated 22-Nov-2013. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is CEFOXITIN FOR INJECTION used for?
Treatment of intra-abdominal, gynecological, septicemia, urinary tract, lower respiratory, bone/joint, and soft tissue infections. Perioperative prophylaxis in abdominal and vaginal surgery.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
What else is CEFOXITIN FOR INJECTION called?
The same molecule, CEFOXITIN, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Cefoxitin | Latin | Iceland |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Product details and regulatory record
| DIN | 02128187 |
|---|---|
| Brand name | CEFOXITIN FOR INJECTION |
| Generic / active ingredient | CEFOXITIN (CEFOXITIN SODIUM) : 1 G |
| Manufacturer | TEVA CANADA LIMITED |
| Strength | 1 G |
| Dosage form | POWDER FOR SOLUTION |
| Route of administration | INTRAVENOUS ; INTRAMUSCULAR |
| Schedule | Prescription |
| ATC code | J01DC01 CEFOXITIN |
| AHFS class | 08:12.07.12 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 22-Nov-2013 |
| Original market date | 1995-12-31 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02128187 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2128187 |
| Brand name | CEFOXITIN FOR INJECTION |
| Active ingredient / INN | CEFOXITIN (CEFOXITIN SODIUM) : 1 G |
| ATC code | J01DC01 |
| ATC anatomical main group | J — Anti-infectives for systemic use |
| ATC therapeutic subgroup | J01 |
| AHFS class | 08:12.07.12 |
| Health Canada schedule | Prescription |
| Biosimilar biologic | No |
| Market authorization holder | TEVA CANADA LIMITED |
How is it administered?
Adults: 1-2 g every 6-8 hours (max 12 g/day). Prophylaxis: 2 g prior to surgery, then 2 g every 2-6 hours for 12-24 hours. Adjust dose in renal impairment. IV or IM administration.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store at room temperature between 15 and 30°C. Protect from light.
How is it supplied?
1 g (10 mL Type III glass vials), 2 g (20 mL Type III glass vials), 10 g (100 mL Type I Pharmacy Bulk Vial).
Which pack is which?
| Strength on the label | 1 G |
|---|---|
| Dosage form | POWDER FOR SOLUTION |
| Route | INTRAVENOUS ; INTRAMUSCULAR |
| Packaging as described in the monograph | 1 g (10 mL Type III glass vials), 2 g (20 mL Type III glass vials), 10 g (100 mL Type I Pharmacy Bulk Vial). |
| Storage | Store at room temperature between 15 and 30°C. Protect from light. |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Contraindications
Hypersensitivity to cefoxitin or other cephalosporin antibiotics. Not recommended for the treatment of meningitis.
Warnings and precautions
Potential cross-allergenicity with penicillins. Risk of anaphylaxis. Pseudomembranous colitis and severe cutaneous adverse reactions (SCAR) like SJS/TEN have been reported.
Is CEFOXITIN in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Resolved — reported by TEVA CANADA LIMITED, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code J01DC01 CEFOXITIN. 2 of 10 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| CEFOXITIN FOR INJECTION | 2 G | POWDER FOR SOLUTION | TEVA CANADA LIMITED | MARKETED | DIN 02128195 |
| CEFOXITIN FOR INJECTION | 10 G | POWDER FOR SOLUTION | TEVA CANADA LIMITED | CANCELLED POST MARKET | DIN 02240773 |
| CEFOXITIN FOR INJECTION USP | 1 G | POWDER FOR SOLUTION | PFIZER CANADA ULC | CANCELLED POST MARKET | DIN 02291711 |
| CEFOXITIN FOR INJECTION USP | 2 G | POWDER FOR SOLUTION | PFIZER CANADA ULC | CANCELLED POST MARKET | DIN 02291738 |
| MEFOXIN INJ 1GM/VIAL ADD-VANTAG | 1 G | POWDER FOR SOLUTION | MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO. | CANCELLED POST MARKET | DIN 00893668 |
| MEFOXIN INJ 2GM/VIAL ADD-VANTAG | 2 G | POWDER FOR SOLUTION | MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO. | CANCELLED POST MARKET | DIN 00893676 |
| MEFOXIN PWS 1GM/VIAL | 1 G | POWDER FOR SOLUTION | MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO. | CANCELLED POST MARKET | DIN 00663697 |
| MEFOXIN PWS 2GM/VIAL | 2 G | POWDER FOR SOLUTION | MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO. | CANCELLED POST MARKET | DIN 00663700 |
| MEFOXIN PWS INJ 10GM/VIAL | 10 G | POWDER FOR SOLUTION | MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO. | CANCELLED POST MARKET | DIN 01980653 |
Who else supplies CEFOXITIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. CEFOXITIN appears in 7 registered pack listings across 4 markets, published on 4 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How much does CEFOXITIN cost around the world?
CEFOXITIN is listed on 3 national price registers Nexara tracks, across 6 pack listings published on 3 different price bases. What each country publishes is set out below.
| Market | What that country publishes | Brands listed | Pack listings | As of |
|---|---|---|---|---|
| South Africa | single exit price | 3 | 3 | 01 Sep 2026 |
| Greece | producer price (ex-factory) | 2 | 2 | 03 Sep 2026 |
| Iceland | max wholesale | 1 | 1 | 02 Sep 2026 |
Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.